Daratumumab (Intravenous)

Medically reviewed by Drugs.com. Last updated on Apr 15, 2022.

Commonly used brand name(s)

In the U.S.

• Darzalex

Available Dosage Forms:

• Solution

Therapeutic Class: Antineoplastic Agent

Pharmacologic Class: Monoclonal Antibody

Uses for daratumumab

Daratumumab injection is used alone or together with other medicines to treat multiple myeloma (a type of bone marrow cancer). It is used alone in patients who have received at least 3 prior treatments that did not work well, including a proteasome inhibitor and an immunomodulatory agent, or who did not respond to both a proteasome inhibitor and an immunomodulatory agent.

Daratumumab injection is also used in combination with lenalidomide and dexamethasone to treat patients with newly diagnosed multiple myeloma who cannot receive autologous stem cell transplant and patients with relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) multiple myeloma who have received at least 1 previous treatment.

Daratumumab injection is also used together with bortezomib, melphalan, and prednisone to treat patients with newly diagnosed multiple myeloma who cannot receive autologous stem cell transplant.

Daratumumab injection is also used together with bortezomib, thalidomide, and dexamethasone to treat patients with newly diagnosed multiple myeloma who can receive autologous stem cell transplant.

Daratumumab injection is also used in combination with bortezomib and dexamethasone to treat patients with multiple myeloma who have received at least 1 previous treatment.

Daratumumab injection is also used in combination with carfilzomib and dexamethasone to treat patients with relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) multiple myeloma who have received 1 to 3 previous treatments.

Daratumumab injection is also used in combination with pomalidomide and dexamethasone to treat patients with multiple myeloma who have received at least two treatments (including lenalidomide and a proteasome inhibitor).

Daratumumab is to be given only by or under the supervision of your doctor.

Before using daratumumab

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For daratumumab, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to daratumumab or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of daratumumab injection in the pediatric population. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of daratumumab injection in the elderly. However, elderly patients are more likely to have serious unwanted effects (eg, pneumonia, sepsis), which may require caution in patients receiving daratumumab.

Breastfeeding

There are no adequat...